HK Stock Market Move | SICC Co.,Ltd.(02631) rises over 6% as power semiconductors enter a price increase cycle; institutions are bullish on the inflection point for the company's earnings release.
SICC Co.,Ltd. (02631) rose over 6%, up 6.2% as of press time, at HK$68.5, with a turnover of HK$171 million.
SICC Co.,Ltd.(02631) rose over 6%, up 6.2% as of press time, at HK$68.5, with a turnover of HK$171 million.
On the news front, media reports today said a price increase letter purportedly issued by ON Semiconductor has circulated in the market. The letter indicates that ON Semiconductor will implement price adjustments across a broad range of products, effective from October 10, 2026. Currently, AI data centers are taking over from new energy vehicles as the core pricing driver of a new three-year upcycle for power semiconductors. Since the start of this year, major overseas players including Infineon, TI, and STMicroelectronics have raised prices successively.
CMB International pointed out that SICC Co.,Ltd. is currently in a historic window of opportunity marked by the convergence of a triple inflection point: the industry is transitioning from 6-inch to 8-inch wafers, and the company holds a 51.3% share in 8-inch, with its generational advantage continuing to widen during the transition; the industry's supply-demand landscape is set to reverse in 2026, with leaders such as Infineon and STMicroelectronics having completed two rounds of price hikes during the year, pushing products into a channel of rising volumes and prices; the company's gross margin has already recovered to 25.4% in 2Q26, and it is expected to turn profitable for the full year of 2026, with the inflection point for earnings release having arrived.
Related Articles

Shanghai Phoenix Enterprise (600679.SH) plans to list for transfer 100% equity of its subsidiary Jinkai Investment and related creditor's rights.

Hangzhou Seck Intelligent Technology (300897.SZ) wins bid for a related procurement project worth 99.36 million yuan.

Hefei Lifeon Pharmaceutical (003020.SZ): The marketing authorization application for clinical trials of Celecoxib and Tramadol Hydrochloride Tablets has been accepted.
Shanghai Phoenix Enterprise (600679.SH) plans to list for transfer 100% equity of its subsidiary Jinkai Investment and related creditor's rights.

Hangzhou Seck Intelligent Technology (300897.SZ) wins bid for a related procurement project worth 99.36 million yuan.

Hefei Lifeon Pharmaceutical (003020.SZ): The marketing authorization application for clinical trials of Celecoxib and Tramadol Hydrochloride Tablets has been accepted.

RECOMMEND





